The total income for the first half stood at Rs.5587.4 millions (Rs.4454.0 millions), registering a growth of 25.44%.

The Profit Before Tax and the Profit After Tax for the first half stood at Rs.493.3 millions (Rs.293.4 millions) and Rs. 56.2 millions (Rs.258.1 millions) registering a sharp increase of 68.13%, and 38% respectively over the corresponding period in the previous year. 

Templeton Strategic Emerging Markets Fund LDC has converted all its share warrants into equity.

a) China subsidiary

b) US JV

c) restructuring of domestic manufacturing facilities to gain economies of scale & global competitiveness

d) mega API and formulation facilities to enter regulated markets at Hyderabad and,

e) a state-of-the-art R&D center.

The Company expects the benefits from these projects will help the Aurobindo Pharma achieve attractive profit margins and growth rates from next year. The benefits of patents obtained from US PTO for cephalosporins and the patent pipeline shall help the organization to penetrate regulated markets with confidence and aggression.

The dream of Aurobindo Pharma to become an R&D led multinational pharmaceutical company focusing on APIs and generic formulations is materializing fast with healthy bottom lines.